Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to:
- Find out if BAY 43-9006 prevents the growth of tumors
- For patients who have stable cancer status after 3 months of treatment if it is safer
and/or more effective to continue to give BAY 43-9006 or to stop giving BAY 43-9006 at
that time.
- Find out how long the effect of BAY 43-9006 is on tumors. To assess the safety of BAY
43-9006 (sorafenib) in the treatment of advanced refractory cancers.
- Measure the amount of BAY 43-9006 and some of its targets in the blood stream in some
patients.